• Hero Banner
  • ACVCACVC
  • DVM 360
  • Fetch DVM 360Fetch DVM 360
DVM 360
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
By Role
AssociatesOwnersPractice ManagerStudentsTechnicians
Subscriptions
dvm360 Newsletterdvm360 Magazine
News
All News
Association
Breaking News
Education
Equine
FDA
Law & Ethics
Market Trends
Medical
Products
Recalls
Regulatory
Digital Media
dvm360 LIVE!™
Expert Interviews
The Vet Blast Podcast
Medical World News
Pet Connections
The Dilemma Live
Vet Perspectives™
Weekly Newscast
dvm360 Insights™
Publications
All Publications
dvm360
Firstline
Supplements
Top Recommended Veterinary Products
Vetted
Clinical
All Clinical
Anesthesia
Animal Welfare
Behavior
Cardiology
CBD in Pets
Dentistry
Dermatology
Diabetes
Emergency & Critical Care
Endocrinology
Equine Medicine
Exotic Animal Medicine
Feline Medicine
Gastroenterology
Imaging
Infectious Diseases
Integrative Medicine
Nutrition
Oncology
Ophthalmology
Orthopedics
Pain Management
Parasitology
Pharmacy
Surgery
Toxicology
Urology & Nephrology
Virtual Care
Business
All Business
Business & Personal Finance
Buying or Selling a Practice
Hospital Design
Leadership & Personal Growth
Personnel Management
Practice Finances
Practice Operations
Technology
Wellbeing & Lifestyle
Continuing Education
Conferences
Live Conferences
Conference News
Conference Proceedings
Resources
CBD in Pets
Contests
Veterinary Heroes
Partners
Spotlight Series
Team Meeting in a Box
Toolkit
Top Recommended Veterinary Products
Vet to Vet
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us

© 2023 MJH Life Sciences and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Advertisement
By Role
  • Associates
  • Owners
  • Practice Manager
  • Students
  • Technicians
Subscriptions
  • dvm360 Newsletter
  • dvm360 Magazine
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us
  • MJHLS Brand Logo

© 2023 MJH Life Sciences™ and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Presentation Recap: Subcutaneous levetiracetam for epilepsy

September 1, 2011
Jennifer L. Garcia, DVM, DACVIM

From the 2011 ACVIM Forum: A new treatment for epileptic dogs?

Parenteral levetiracetam (Keppra—UCB) rapidly reaches therapeutic concentrations in dogs if given intravenously or intramuscularly. A research abstract presenting data from four healthy dogs showed that subcutaneous administration of levetiracetam exceeded the therapeutic range within 15 minutes of administration and remained elevated for at least seven hours.1 The drug was well-tolerated, and no adverse events were noted. Further research is warranted, but subcutaneous levetiracetam may provide an alternative to both clinical and at-home emergency management of epilepsy.

Advertisement

This "Presentation Recap" summary from the 2011 American College of Veterinary Internal Medicine (ACVIM) Forum, which took place in Denver, Colo., was contributed by Jennifer L. Garcia, DVM, DACVIM, a veterinary internal medicine consultant in Houston, Texas.

REFERENCE

1. Hardy BT, Patterson EE, Cloyd JM. Subcutaneous administration of levetiracetam in healthy dogs (abst). J Vet Intern Med 2011;25(3):741.

Related Content:

Neurology
A veterinary neurologist’s clinical approach to epilepsy
A veterinary neurologist’s clinical approach to epilepsy
Top dvm360 articles of 2022: #6
Top dvm360 articles of 2022: #6
Top dvm360 articles of 2022: #12
Top dvm360 articles of 2022: #12

Advertisement

Latest News

Drug for acute onset of canine pancreatitis is launched on the US market

New Automatic 2-in-1 Pet Feeder and Water Dispenser launched

PetHub launches AI tools for pet owners

Prairie dog pups emerge from underground at Maryland Zoo

View More Latest News
Advertisement